高级检索

新型消化道黏膜隆起凝胶的临床前有效性与安全性评价——活体猪模型实验

Preclinical efficacy and safety evaluation of a novel gastrointestinal mucosal elevation gel in vivo porcine model

  • 摘要:
    目的 评估新型消化道黏膜隆起凝胶在活体猪消化道模型中的有效性和安全性。
    方法 选用8只健康白猪,分为隆起高度评价(n=2)和安全性评价(n=6),将样品(消化道黏膜隆起凝胶样品)与对照品(一次性使用内镜消化道黏膜下填充剂)分别注射于猪胃胃窦与胃体黏膜下。在隆起高度评价中,注射后观察并记录即刻和30 min时间点黏膜隆起形态、持久性以及临床安全性。在安全性评价中,注射后行内镜下黏膜切除术,观察并记录即刻和7 d时间点黏膜隆起外形、产品有效性及临床安全性。所有动物观察完成后处死并取材切除组织进行组织病理学评价。
    结果 在隆起高度评价中,样品组术后即刻呈陡峭型隆起,较对照品组隆起外形更为明显(P=0.019);术后30 min时2个(25%)位点隆起外形出现轻微塌陷,较对照品组(8个全部塌陷)隆起高度持久性显著增加(P<0.001)。在安全性评价中,术后样品组平均创面面积为1.77 mm2,显著低于对照品组(2.65 mm2P<0.001),两组平均注射剂量、隆起部位平均切除时间、整块切除率差异均无统计学意义。术后即刻样品组均见轻度溃疡,仅1个(12.5%)位点见轻微出血;术后7 d样品组均未见出血、穿孔、溃疡或水肿的情况,与对照品组差异均无统计学意义。组织病理学评价显示,术后即刻样品组胃窦与胃体组织见中度损伤和轻度水肿,伴轻度炎症细胞浸润;7 d时间点样品组胃窦组织见中度损伤,轻微出血和水肿,伴轻度炎症细胞浸润,1个(12.5%)位点组织见感染,胃体组织未见出血,见中度损伤和轻度水肿,伴轻度炎症细胞浸润,3个(37.5%)位点组织见感染,均与对照品组差异无统计学意义。
    结论  新型消化道黏膜隆起凝胶在临床前动物实验中隆起外形陡峭,隆起高度持久,具有良好的有效性和安全性,展现出巨大的临床应用潜力。

     

    Abstract:
    Objective To evaluate the efficacy and safety of a novel gastrointestinal mucosal elevation gel in vivo porcine model.
    Methods Eight healthy white pigs were selected, which were divided into bump height evaluation (n=2) and safety evaluation (n=6). The sample (alimentary canal mucosa bump gel sample) and the control sample (disposable endoscopic submucosal filler of alimentary canal) were respectively injected into the submucosa of pig gastric antrum and gastric body. In the evaluation of elevation height, the morphology, persistence, and clinical safety of mucosal elevation were observed and recorded immediately and 30 minutes after injection. In safety evaluation, endoscopic mucosal resection was performed after injection, and the mucosal protrusion shape, product efficacy, and clinical safety were observed and recorded at immediate and 7-day time points. After observation, all animals were euthanized and tissue samples were collected and excised for histopathological evaluation.
    Results In elevation height evaluation, sample group showed a steep elevation immediately after surgery, exhibiting a more pronounced elevation morphology compared to control group (P=0.019). Only two(25%) sites of the elevation showed slight collapse in 30 minutes after surgery, and the durability notably increased compared to control group (8 all collapsed, P<0.001). In safety evaluation, the average trauma area of sample group was 1.77 mm2, which was significantly lower than control group (2.65 mm2, P<0.001). There was no statistical difference among average injection dose per unit area, surgical time per unit area, and en bloc resection rate. Sample groupt showed mild ulcers and only 1 (12.5%) site of mild bleeding at immediate time point after surgery. No bleeding, perforation, ulcer or edema was observed in sample group 7 days after surgery, and no statistical difference was identified compared to control group. Histopathological evaluation found that the gastric antrum and body tissues exhibited moderate injury and mild edema at immediate time point, accompanied by mild inflammatory cellular infiltration. At 7d time point, gastric antrum tissues demonstrated moderate injury, mild edema and mild inflammatory cellular infiltration, with 1 (12.5%) site of tissues infected, while in gastric body tissues, no bleeding was observed, whereas moderate injury and mild edema were evident, accompanied by mild inflammatory cellular infiltration and 3 (37.5%) sites of tissues infected, all of which were not statistically different from control group.
    Conclusion The novel gastrointestinal mucosal elevation gel exhibited steep elevation morphology, long-lasting elevation height, and favorable efficacy and safety in preclinical animal trials, showing enormous clinical application potential.

     

/

返回文章
返回